Journal of Thrombosis and Thrombolysis

Papers
(The TQCC of Journal of Thrombosis and Thrombolysis is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Neutrophil extracellular traps and thrombosis in COVID-19188
Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review64
Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients54
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum42
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting41
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-1940
Incidence of thrombotic complications in COVID-1940
Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus40
Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series38
Pulmonary thrombosis in Covid-19: before, during and after hospital admission36
Major bleeding complications in critically ill patients with COVID-19 pneumonia32
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis31
SARS-CoV-2 infection and thrombotic complications: a narrative review29
COVID-19 and its sequelae: a platform for optimal patient care, discovery and training28
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage28
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation27
Serotonin: a platelet hormone modulating cardiovascular disease27
A comprehensive review of vascular complications in COVID-1926
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy25
Thrombosis in VEXAS syndrome25
External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-1923
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-1922
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines21
Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)21
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics20
Arterial and venous involvement in Behçet’s syndrome: a narrative review19
Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease19
Lupus anticoagulant and mortality in patients hospitalized for COVID-1918
Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic18
Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review18
Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?18
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials18
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design17
CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients17
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis17
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients16
Roles of factor Xa beyond coagulation16
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-1916
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis16
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome16
Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease16
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies15
COVID 19 infection associated with thrombotic thrombocytopenic purpura14
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes14
Tissue factor: a neglected role in cancer biology14
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population14
Association of ABO blood group type with cardiovascular events in COVID-1914
A case of thrombotic thrombocytopenic purpura associated with COVID-1914
One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic14
Global coagulation assays in hypercoagulable states14
Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-1914
ST-segment elevation in patients with COVID-19: a systematic review14
Prior use of anticoagulation is associated with a better survival in COVID-1913
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia13
Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score13
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors13
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor13
Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients13
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis13
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri12
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality12
LncRNA LSINCT5/miR-222 regulates myocardial ischemia‑reperfusion injury through PI3K/AKT pathway12
Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: a prospective cohort study12
Neurological manifestations of thrombotic microangiopathy syndromes in adult patients12
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis12
Outpatient management of chronic warfarin therapy at a pharmacist-run anticoagulation clinic during the COVID-19 pandemic12
Immature platelets in patients with Covid-19: association with disease severity12
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study11
Combining lung ultrasound and Wells score for diagnosing pulmonary embolism in critically ill COVID-19 patients11
Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management11
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography11
Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension11
Impact of the pandemic of COVID-19 on emergency attendance for stroke and acute myocardial infarction in Beijing, China11
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone11
Circ_0003204 knockdown protects endothelial cells against oxidized low-density lipoprotein-induced injuries by targeting the miR-491-5p-ICAM1 pathway11
Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction11
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism11
Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation11
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer11
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism11
COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles11
Causal effect of renal function on venous thromboembolism: a two-sample Mendelian randomization investigation10
Biomarkers associated with coronary high-risk plaques10
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?10
Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation10
Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm10
Heparin-induced thrombocytopenia in extra-corporeal membrane oxygenation: epidemiology, outcomes, and diagnostic challenges10
Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?10
Inflammatory cytokines enhance procoagulant activity of platelets and endothelial cells through phosphatidylserine exposure in patients with essential hypertension10
Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry)10
LncRNA BANCR induced vascular smooth muscle cell proliferation by downregulating miR-34c methylation in atherosclerosis10
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)10
Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes9
The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury9
MicroRNA-29b reduces myocardial ischemia–reperfusion injury in rats via down-regulating PTEN and activating the Akt/eNOS signaling pathway9
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS9
Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing9
MicroRNA-342-3p loaded by human umbilical cord mesenchymal stem cells-derived exosomes attenuates deep vein thrombosis by downregulating EDNRA9
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study9
Downregulating LncRNA XIST attenuated contrast-induced nephropathy injury via regulating miR-133a-3p/NLRP3 axis9
Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus9
The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study9
An abbreviated Caprini model for VTE risk assessment in trauma9
International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests9
The risk of venous thromboembolism and physical activity level, especially high level: a systematic review9
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE tr9
Overexpression of miR-1298 attenuates myocardial ischemia–reperfusion injury by targeting PP2A9
0.060195922851562